Skip to content
StockMarketAgent

Abbott Laboratories (ABT)

NYSE: ABT · Real-Time Price · USD
$84.3
-2.69 (-3.1%)· Live
StockMarketAgent Research

Our analysis: ABT rated Strong Buy

ABT is rated Strong Buy at $84.32 versus the reconciled fair value midpoint of $107.02, implying +26.92% upside/downside. Confidence is separately disclosed at 88/100.

Fair value (mid)
$107 / share
$87.2 – $127
Upside to FV
+26.9%
from $84.3
Confidence
88/100
Moat
9/10
Read full analysis →View archive · 24mo
9-phase methodology · same model every month
Biggest opportunityBull case · highest-impact upside lever

Bull: Innovation in Medical Devices and sustained recovery in routine Diagnostics outpace expectations, yielding significant operating leverage. FCF conversion accelerates, enabling aggressive dividend hikes and synergistic acquisitions without compromising the balance sheet.

Biggest riskTop kill scenario by severity
Libre Market Share Loss

Libre Market Share Loss: Next-gen competitive continuous glucose monitors or GLP-1 drug advancements severely erode FreeStyle Libre adoption, cratering high-margin medical device growth.

Recommended actionConviction: high
Strong Buy

ABT is rated Strong Buy at $84.32 versus the reconciled fair value midpoint of $107.02, implying +26.92% upside/downside. Confidence is separately disclosed at 88/100.

Position sizing playbook →
Market cap$146.9B
Revenue (ttm)45.1B
Net income (ttm)6.3B
EPS (ttm)$3.57
Shares out1.7B
P/E (trailing)23.6x
P/E (forward)13.9x
Dividend$2.52 (2.99%)
Volume10,913,578
Beta0.65
Price target$131+55.2%
Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm)
45.1B
Net income (ttm)
6.3B
EPS (ttm)
$3.57
P/E (trailing)
23.6x
P/E (forward)
13.9x
Market cap
$146.9B

Scenarios & expected return

Probability-weighted: +16.1% expected return to fair value
Bull20%
Price target
$127.26
+50.9% from spot

Innovation in Medical Devices and sustained recovery in routine Diagnostics outpace expectations, yielding significant operating leverage. FCF conversion accelerates, enabling aggressive dividend hikes and synergistic acquisitions without compromising the balance sheet.

  • Revenue growth strictly exceeds the 13% near-term forecast.
  • Operating margins permanently expand beyond the 18% threshold.
  • Terminal PE multiple expands to 18x reflecting med-device dominance.
Base60%
Price target
$107.02
+26.9% from spot

Following a volatile pandemic-era revenue trajectory, the company stabilizes into a moderate growth phase supported by its medical device and nutrition segments, reliably sustaining its 67% dividend payout ratio and robust intrinsic cash generation.

  • Revenue growth converges smoothly to a 3.5% terminal rate.
  • Operating margins effectively normalize and hold at 17%.
  • Terminal PE holds steady at 16x matching mature dividend peers.
Bear20%
Price target
$87.24
+3.5% from spot

Macroeconomic headwinds, persistent FX drag, and intense pricing pressure in Established Pharmaceuticals and Nutrition compress operating margins. Subpar accounting metrics foreshadow structural profitability deterioration, severely limiting dividend growth.

  • Macroeconomic headwinds heavily persist restricting hospital spend.
  • Pricing pressure compresses operating margins structurally to 15%.
  • Terminal valuation multiple contracts to 14x as growth stalls.

Valuation models & bridge

Each model produces an independent fair value. Weighted average = $107.
ModelWeightFV / sharevs spotContribution
FCFF DCF30%$129+52.9%
Forward earnings30%$97.9+16.1%
Multi stage moat fade20%$98.5+16.8%
Discounted earnings10%$136+61.9%
Ddm10%$56.4-33.2%
Reverse DCF0%$0.00-100.0%
Owner earnings0%$152+80.4%
Peg adjusted peer0%$75.0-11.1%
Residual income0%$0.00-100.0%
Composite FV (weighted)100%$107+26.9%

Sensitivity: Ke × terminal growth

Ke ↓ / g →1.5%2.0%2.5%3.0%3.5%
5.1%$137$158$187$187$187
6.1%$107$120$137$158$187
7.1%$88.0$96.6$107$120$137
8.1%$74.7$80.8$88.0$96.6$107
9.1%$64.9$69.5$74.7$80.8$88.0

Scorecard

Factor radar (left) · 9-category weighted composite (right)
ValuationManagementBalanceProfitabilityRevenueRiskCompetitiveEarningsCapital
Valuation1.5
Management6.4
Balance Sheet6.0
Profitability5.5
Revenue Growth6.0
Risk Assessment7.5
Competitive Moat9.0
Earnings Quality3.5
Capital Efficiency5.0
Weighted composite
5.6/10
Mixed
CategoryWeightScoreReading
Valuation11%1.5
Management11%6.4
Balance Sheet11%6.0
Profitability11%5.5
Revenue Growth11%6.0
Risk Assessment11%7.5
Competitive Moat11%9.0
Earnings Quality11%3.5
Capital Efficiency11%5.0

Position sizing & entry playbook

Pre-committed rules, followed irrespective of news flow.
Conviction tier
High
Confidence 88/100
Target weight
Core portfolio holding; limit to maximum 5% weighting given current accounting quality flags and low F-score.
of equity sleeve
Initiate at the current price of $84.32, which offers an attractive 26.9% discount to the $107.02 base fair value.
Current / pullbacks
Current price
Today’s last trade
$84.3
Trim position as price approaches the $107.02 mid-point; execute a hard exit if OCF/NI ratio breaks below 1.0 or the dividend is cut.
Thesis break
Risk to thesis
  • Trim position as price approaches the $107.02 mid-point; execute a hard exit if OCF/NI ratio breaks below 1.0 or the dividend is cut.
Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming
DateLoading
Window—
EPS estimate—
Revenue estimate—

Sector percentile context

Refreshed 2026-05-10 22:07 UTC
Forward P/E13.9
P25 n/aP50 n/aP75 n/a
Trailing P/E0
P25 n/aP50 n/aP75 n/a
ROE12.3
P25 n/aP50 n/aP75 n/a
ROIC9.6
P25 n/aP50 n/aP75 n/a
Benchmarks · 1M
S&P 500n/a
Nasdaq Compositen/a
Dow Jones Industrial Averagen/a
Russell 2000n/a

All ABT indicators

Market & fundamental data
Available fields
283
Groups with data
11
Currency
USD
Showing 283 of 283 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

25
MetricValue
Cik
0000001800
Company name
Abbott Laboratories
Country
United States
Country code
US
Cusip
002824100
Employees
115,000
Employees Change
1,000%
Employees Change Percent
0.88
Enterprise value
$173.7B
Exchange
NYSE
Financial currency
USD
First seen
2026-05-09
In Index
SP500
Industry
Medical Devices
Isin
US0028241000
Last refreshed
2026-05-10
Market cap
$146.9B
Market cap category
Large-Cap
Price
$84.32
Price currency
USD
Rev Per Employee
392,469.57x
Sector
Healthcare
Sic
2834
Symbol
ABT
Website
https://www.abbott.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

17
MetricValue
Earnings Yield
4.26%
EV Earnings
27.78x
EV Sales Forward
3.34x
EV/EBIT
20.24x
EV/EBITDA
14.79x
EV/FCF
23.54x
EV/Sales
3.85x
FCF yield
5.02%
Forward P/E
15.05x
P/B ratio
2.82x
P/E ratio
23.62x
P/S ratio
3.25x
PE Ratio10 Y
50.34x
PE Ratio3 Y
27.72x
PE Ratio5 Y
27.88x
PEG ratio
1.59x
PS Forward
2.82x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

26
MetricValue
EBIT Margin
19.01%
EBITDA Margin
26.02%
FCF margin
16.35%
Gross margin
56.5%
Gross Profit
$25.5B
Gross Profit Growth
7.63%
Gross Profit Growth Q
6.52%
Gross Profit Growth3 Y
3.39%
Gross Profit Growth5 Y
3.61%
Net Income
$6.3B
Net Income Growth
-53.52%
Net Income Growth Q
-18.72%
Net Income Growth Years
0%
Net Income Growth3 Y
2.62%
Net Income Growth5 Y
1.88%
Pretax Margin
18.03%
Profit Margin
13.91%
Profit Per Employee
$54,365
Profitable Years
35
ROA
5.59
Roa5y
6.84
ROCE
9.32
ROE
12.33
Roe5y
19.7
ROIC
9.63
Roic5y
14.92

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

29
MetricValue
Cagr10y
10.35%
Cagr15y
10.66%
Cagr1y
-35.78%
Cagr20y
9.82%
Cagr3y
-6.98%
Cagr5y
-4.88%
Div CAGR10
9.33%
Div CAGR3
7.57%
Div CAGR5
8.54%
EPS Growth
-53.65
EPS Growth Q
-19.74
EPS Growth Years
0
EPS Growth3 Y
2.78
EPS Growth5 Y
2.27
FCF Growth
10.83%
FCF Growth Q
-1.82%
FCF Growth3 Y
2.64%
FCF Growth5 Y
-0.61%
OCF Growth
5.74%
OCF Growth Q
-7.2%
OCF Growth10 Y
12.67%
OCF Growth3 Y
3.01%
OCF Growth5 Y
-0.74%
Revenue Growth
6.59x
Revenue Growth Q
7.78x
Revenue Growth Quarters
10x
Revenue Growth Years
2x
Revenue Growth3 Y
2.83x
Revenue Growth5 Y
3.87x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

22
MetricValue
Asset Turnover
$0.47
Assets
$110.4B
Cash
$7.3B
Current Assets
$25.5B
Current Liabilities
$18.4B
Debt
$34.1B
Debt EBITDA
$2.81
Debt Equity
$0.65
Debt FCF
$4.63
Equity
$52.7B
Interest Coverage
16.01
Liabilities
$57.7B
Long Term Assets
$84.9B
Long Term Liabilities
$39.4B
Net Cash
$-26.8B
Net Cash By Market Cap
$-18.28
Net Debt EBITDA
$2.29
Net Debt Equity
$0.51
Net Debt FCF
$3.64
Tangible Book Value
$-1B
Tangible Book Value Per Share
$-0.59
WACC
6.56

Liquidity

Current-asset coverage and working-capital efficiency metrics.

6
MetricValue
Current ratio
1.39
Inventory Turnover
2.88
Net Working Capital
$4.3B
Quick ratio
0.84
Working Capital
$7.1B
Working Capital Turnover
$5.22

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

10
MetricValue
Buyback Yield
-0.03%
Dividend Growth
7.02%
Dividend Growth Years
54%
Dividend per share
$2.52
Dividend Years
56
Dividend Yield
2.99%
Ex Div Date
2026-04-15
Last Dividend
$0.63
Payout Frequency
Quarterly
Payout Ratio
68.35%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

42
MetricValue
10Y total return
167.81%
1Y total return
-35.77%
200-day SMA
119.6
3Y total return
-19.52%
50-day SMA
101.2
50-day SMA vs 200-day SMA
50under200
5Y total return
-22.13%
All Time High
142.6
All Time High Change
-40.87%
All Time High Date
2021-12-27
All Time Low
0.24
All Time Low Change
35,283.97%
All Time Low Date
1974-10-04
ATR
2.26
Beta
0.65
Beta1y
0.24
Beta2y
0.24
Ch YTD
-32.7
High
87.31
High52
139.1
High52 Date
2025-06-24
High52ch
-39.36%
Low
84.08
Low52
84.08
Low52 Date
2026-05-08
Low52ch
0.29%
Ma50ch
-16.72%
Premarket Change Percent
0.49
Premarket Price
$87.44
Premarket Volume
8,744
Price vs 200-day SMA
-29.51%
RSI
22.66
RSI Monthly
33.35
RSI Weekly
18.61
Sharpe ratio
-1.92x
Sortino ratio
-2.08
Total Return
2.96%
Tr YTD
-31.93
Tr15y
357.2%
Tr1m
-16.68%
Tr1w
-5.75%
Tr3m
-23.44%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

18
MetricValue
Analyst Count
20
Analyst Count Top
3
Analyst Price Target Top
$125
Analyst Ratings
Strong Buy
Analyst Ratings Top
Strong Buy
Earnings EPS Estimate
$1.14
Earnings EPS Estimate Growth
4.59
Earnings Revenue Estimate
11,007,093,250x
Earnings Revenue Estimate Growth
6.27x
Operating Income
$8.6B
Operating Income Growth
9.76
Operating Income Growth Q
-18.26
Operating Income Growth3 Y
3.54
Operating Income Growth5 Y
4.05
Operating margin
19.01
Price target
$131
Price Target Change
$55.24
Price Target Change Top
$48.64

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

11
MetricValue
Float
1,731,228,666%
Float Percent
99.39%
Net Borrowing
17,897,000,000
Shares Insiders
0.49%
Shares Institutions
80.5%
Shares Out
1,741,812,429
Shares Qo Q
0%
Shares Yo Y
0.03%
Short Float
1.26%
Short Ratio
1.71
Short Shares
1.25

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

77
MetricValue
Adjusted FCF
$6.7B
Average Volume
13,938,225.6x
Bv Per Share
29.89
CAPEX
$-2.1B
Ch10y
122.1
Ch15y
60.55
Ch1m
-17.2
Ch1w
-5.75
Ch1y
-37.05
Ch20y
97.15
Ch3m
-23.92
Ch3y
-24.21
Ch5y
-29.11
Ch6m
-33.27
Change
-3.09%
Change From Open
-3.26
Close
87.01
Days Gap
0.17
Depreciation Amortization
3,163,000,000
Dollar Volume
920,232,897
Earnings Date
2026-04-16
Earnings Time
bmo
EBIT
$8.6B
EBITDA
$11.7B
EPS
$3.57
F Score
5
FCF
$7.4B
FCF EV Yield
4.25x
FCF Per Share
$4.24
Financing CF
13,059,000,000
Fiscal Year End
December
Founded
1,888
Goodwill
35,221,000,000
Graham Number
48.99891
Graham Upside
-41.89
Income Tax
$1.9B
Investing CF
-22,276,000,000
Is Primary Listing
1
Is Spac
No
Last Earnings Date
2026-04-16
Last Report Date
2026-03-31
Last Split Date
1998-06-01
Last Split Type
Forward
Last10k Filing Date
2026-02-20
Lynch Fair Value
$17.85
Lynch Upside
-78.83
Ma150
115.6
Ma150ch
-27.06%
Ma20
92.51
Ma20ch
-8.85%
Net CF
271,000,000
Next Earnings Date
2026-07-16
Open
87.16
Optionable
Yes
P FCF Ratio
19.91
P OCF Ratio
15.52
Payment Date
2026-05-15
Position In Range
7.43
Post Close
84.32
Postmarket Change Percent
0.15
Postmarket Price
$84.45
Ppne
12,377,000,000
Pre Close
87.01
Price Date
2026-05-08
Price EBITDA
$12.51
Relative Volume
0.78x
Revenue
45,134,000,000x
SBC By Revenue
1.53x
Share Based Comp
692,000,000
Tax By Revenue
4.12x
Tax Rate
22.87%
Tr20y
550.61%
Tr6m
-32.51%
Us State
Illinois
Views
256
Volume
10,913,578
Z Score
3.65

Deeper analysis on ABT

14 sections in the full report · jump straight to what you need
Forecast
Bull, base, and bear cases with expected-return framing.
→
Valuation
Fair-value bridge, DCF, owner earnings, and peer multiples.
→
Sensitivity
Cost-of-equity and terminal-growth stress table.
→
Risks
Kill scenarios, soft-pass flags, and downside catalysts.
→
Earnings
Next earnings setup and beat / inline / miss thresholds.
→
Position sizing
Entry, exit, conviction, and quarterly monitoring rules.
→
Financials
Revenue, margins, cash flow, and balance-sheet context.
→
Peers
Relative valuation and profitability against the cohort.
→
Moat
Economic-profit evidence and competitive advantage risk.
→
Industry cycle
Sector phase, capital cycle, and secular tailwinds.
→
Scorecard
Six-factor overlay and 9-category weighted scorecard.
→
Recommendation
Final action, action steps, opportunity, and biggest risk.
→
Perspectives
Growth, value, and income investor reads.
→
Archive
Prior monthly reports and rating changes.
→

Frequently asked questions

About this ABT report
What is the current ABT stock rating?
Abbott Laboratories is currently shown with Strong Buy in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.
Where can I read the full ABT analysis?
The full report lives at /stocks/ABT/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.
What fair-value range is used for ABT?
The latest report frames ABT around $87 to $127. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.
How often is the ABT page updated?
The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.
Strong BuyABT · Fair value $107+26.9% · Confidence 88/100
Read full analysis →